γ-L-glutamyl-L-cysteine ethyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: γ-L-glutamyl-L-cysteine ethyl ester
• 英文别名: 2-Amino-5-[(1-ethoxy-1-oxo-3-sulfanylpropan-2-yl)amino]-5-oxopentanoic acid
• 化学式: C₁₀H₁₈N₂O₅S
• 分子量: 278.329
• InChiKey: IVEKVTHFAJJKGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• [EN] METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2019060634A1

  公开（公告）日：2019-03-28

  The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

  这项发明涉及治疗囊性氨基酸病和其他对半胱氨酸敏感的疾病的方法，包括在体内给予可转化为半胱氨酸的二硫化物。该方法可以包括向受试者单独给予还原剂，以增加半胱氨酸在给予二硫化物后产生的生物利用度，并延长血浆药代动力学特性。该方法允许受试者体内维持持续的半胱氨酸血浆浓度。
• AGENT FOR IMPROVING FEED CONVERSION RATE, AGENT FOR IMPROVING SURVIVAL RATE, AGENT FOR IMPROVING NUMBER OF EGGS LAID BY EGG-LAYING HENS, METHOD FOR GIVING SAME TO ANIMALS, AND FEED
  申请人：Tsubakisangyo Co., Ltd.

  公开号：EP3466268A1

  公开（公告）日：2019-04-10

  An agent for improving a feed conversion rate, an agent for improving a survival rate, an agent for improving the number of eggs laid by an egg-laying hen, a method of giving these agents to animals, and a feed which can directly and significantly improve the productivity of livestock farms are provided. At least one effective ingredient selected from cysteine and cysteine derivatives is given to animals. The effective ingredient may be added to drinking water, or may be added to the feed. Examples of the cysteine and cysteine derivatives can include acetylcysteine (NAC), S-methyl-L-cysteine (SMC), cysteine malate, and acetylcysteine amide.

  提供了一种提高饲料转化率的制剂、一种提高存活率的制剂、一种提高产蛋母鸡产蛋数量的制剂、一种给动物使用这些制剂的方法，以及一种可直接显著提高畜牧场生产率的饲料。至少一种选自半胱氨酸和半胱氨酸衍生物的有效成分被给予动物。有效成分可以添加到饮用水中，也可以添加到饲料中。半胱氨酸和半胱氨酸衍生物的例子可包括乙酰半胱氨酸（NAC）、S-甲基-L-半胱氨酸（SMC）、半胱氨酸苹果酸盐和乙酰半胱氨酸酰胺。
• Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
  申请人：Thiogenesis Therapeutics, Inc.

  公开号：US11173135B2

  公开（公告）日：2021-11-16

  The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.

  本发明的特点是组合物、方法和试剂盒含有(i)一种或多种可在体内转化为半胱胺的半胱胺前体化合物，以及(ii)可选的增强这种转化的制剂，配制成一系列半胱胺的药代动力学特征，可根据不同的患者和疾病量身定制。本发明的另一个特点是，在治疗胱氨酸沉着症和其他半胱胺敏感性疾病时，治疗物质的给药方式各不相同。特别是将活性成分与药用辅料相结合的制剂，可使半胱胺的血浆浓度保持稳定。
• COMPOSITIONS FOR CONTROLLED RELEASE OF CYSTEAMINE AND SYSTEMIC TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS
  申请人：Thiogenesis Therapeutics, Inc.

  公开号：EP3429573A1

  公开（公告）日：2019-01-23
• METHOD FOR IMPROVING FEED CONVERSION RATE,
  申请人：Tsubakisangyo Co., Ltd.

  公开号：EP3466268B1

  公开（公告）日：2022-02-09